



Emily S. Mahoney

ASSOCIATE

781 795 4726 direct

emily.mahoney@faberlawgroup.com

Industry Experience

Summer Associate

Harvard Management Company

Legal Intern

Partners Healthcare, Office for Interactions with Industry

Clinical Research Coordinator

Ragon Institute of MGH, MIT and Harvard (formerly Partners AIDS Research Center)

Emily's experience in healthcare and clinical research settings serves her clients well. She advises both public and private companies at all stages of development on a variety of transactional contracting matters, with a particular focus on clinical trial agreements and related ancillary agreements, manufacturing agreements, vendor services agreements, and SaaS and other software and technology related agreements.

EXPERIENCE

Worked for a large consulting company advising pharmaceutical companies on how to develop a robust compliance program.

Ragon Institute of MGH, MIT and Harvard (formerly Partners AIDS Research Center)

Clinical Research Coordinator

- Assisted with research into infectious diseases

RECENT CLIENT WORK

- Negotiated multiple GMP services agreements for packaging and labeling services and for warehousing and distribution services
- Negotiated multiple software license and services agreements and SaaS agreements for a range of software products
- Negotiated numerous services agreements with contract research organizations to assist clients with clinical trials

Bar Admissions

- Massachusetts

Education

- Tufts University School of Medicine, M.P.H.
- Northeastern University School of Law, J.D.
- Washington University in St. Louis, B.A., *magna cum laude*, with Honors



Emily S. Mahoney (continued)

- Negotiated multiple clinical development and manufacturing agreements with various CMOs
- Assisted with the license of intellectual property assets to a newly formed company and the drafting and negotiation of multiple contracts to support the relationship between the licensor and licensee, including a Supply Agreement and multiple services agreements
- Assisted with the sale of AesRx to Baxter (now Baxalta)

faber